Treatment research in prison: Problems and solutions in a randomized trial

References

• Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, Koepsell TD. Release from prison–A high risk of death for former inmates. New England Journal of Medicine 2007; 356: 157–165
   PubMed Web of Science ®Google Scholar
• Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland 1996–99. Addiction 2003; 98: 185–190
   PubMed Web of Science ®Google Scholar
• Brahen LS, Henderson RK, Capone T, Kordal N. Naltrexone treatment in a jail work-release program. Journal of Clinical Psychiatry 1984; 45: 49–52
   PubMed Web of Science ®Google Scholar
• Bruce RD, Schleifer RA. Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention. International Journal of Drug Policy 2008; 19: 17–23
   PubMedGoogle Scholar
• Butzin CA, Martin SS, Inciardi JA. Treatment during transition from prison to community and subsequent illicit drug use. Journal of Substance Abuse Treatment 2005; 28: 351–358
   PubMed Web of Science ®Google Scholar
• Caplan AL. Ethical issues surrounding forced, mandated, or coerced treatment. Journal of Substance Abuse Treatment 2006; 31: 117–120
   PubMed Web of Science ®Google Scholar
• Chan KY. The Singapore naltrexone community-based project for heroin addicts compared with drugfree community-based program: The first cohort. Journal of Clinical Forensic Medicine 1996; 3: 87–92
   PubMedGoogle Scholar
• Chiang CN, Hollister LE, Gillespie HK, Foltz RL. Clinical evaluation of a naltrexone sustained-release preparation. Drug and Alcohol Dependence 1985; 16: 1–8
   PubMed Web of Science ®Google Scholar
• Collins LM, Murphy SA, Bierman KL. A conceptual framework for adaptive preventive interventions. Prevention Science 2004; 5: 185–196
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: Novel treatment for opioid dependence. Expert Opinion on Investigational Drugs 2007; 16: 1285–1294
   PubMed Web of Science ®Google Scholar
• Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, O'Brien CP. Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment 1997; 14: 529–534
   PubMed Web of Science ®Google Scholar
• Cropsey KL, Villalobos GC, St Clair CL. Pharmacotherapy treatment in substance-dependent correctional populations: A review. Substance Use and Misuse 2005; 40: 1983–1988
   PubMed Web of Science ®Google Scholar
• Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction 2005; 100: 820–828
   PubMed Web of Science ®Google Scholar
• Fram DH, Marmo J, Holden R. Naltrexone treatment–The problem of patient acceptance. Journal of Substance Abuse Treatment 1989; 6: 119–122
   PubMed Web of Science ®Google Scholar
• Friestad C, Hansen IL. Levekaar blant innsatte. [Norwegian] (report 429). Fafo research foundation, Oslo 2004
   Google Scholar
• Gatherer A, Moller L, Hayton P. The World Health Organization European Health in prisons project after 10 years: Persistent barriers and achievements. American Journal of Public Health 2005; 95: 1696–1700
   PubMed Web of Science ®Google Scholar
• Gjersing LR, Butler T, Caplehorn JR, Belcher JM, Matthews R. Attitudes and beliefs towards methadone maintenance treatment among Australian prison health staff. Drug & Alcohol Review 2007; 26: 501–508
   PubMed Web of Science ®Google Scholar
• Helgeland IM. ‘Catch 22’ of research ethics: Ethical dilemmas in follow-up studies of marginal groups. Qualitative Inquiry 2005; 11: 549–569
   Web of Science ®Google Scholar
• Hodgson P, Parker A, Seddon T. Doing drugs research in the criminal justice system: Some notes from the field. Addiction Research and Theory 2006; 14: 253–264
   Web of Science ®Google Scholar
• Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug and Alcohol Dependence 2005; 79: 351–357
   PubMed Web of Science ®Google Scholar
• Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: Preliminary findings. Journal of Substance Abuse Treatment 2002; 22: 141–147
   PubMed Web of Science ®Google Scholar
• Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: Report of post-release outcomes. American Journal of Drug and Alcohol Abuse 2005; 31: 433–454
   PubMed Web of Science ®Google Scholar
• Kinlock TW, Gordon MS, Schwartz RP, O’grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: Results at 1-month post-release. Drug and Alcohol Dependence 2007; 91: 220–227
   PubMed Web of Science ®Google Scholar
• Lavori PW, Dawson R. Dynamic treatment regimes: Practical design considerations. Clinical Trials 2004; 1: 9–20
   PubMedGoogle Scholar
• Liebling A. Whose side are we on? Theory, practice and allegiances in prisons research. British Journal of Criminology 2001; 41: 472–484
   Web of Science ®Google Scholar
• Lines R. From equivalence of standards to equivalence of objectives: The entitlement of prisoners to health care standards higher than those outside prisons. International Journal of Prisoner Health 2006; 2: 269–280
   Google Scholar
• Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-Release Naltrexone For Opioid Dependence. Cochrane Database of Systematic Reviews 2008, 2, Art. No.: CD006140. DOI: 10.1002/14651858. CD006140.pub 2
   PubMedGoogle Scholar
• Marlowe DB. Depot naltrexone in lieu of incarceration: A behavioral analysis of coerced treatment for addicted offenders. Journal of Substance Abuse Treatment 2006; 31: 131–139
   PubMed Web of Science ®Google Scholar
• Martin WR, Sandquist VL. A sustained release depot for narcotic antagonists. Archives of General Psychiatry 1974; 30: 31–33
   PubMed Web of Science ®Google Scholar
• McKenzie M, Macalino G, McClung C, Shield DC, Rich JD. Opiate replacement therapy at time of release from incarceration: Project MOD, a pilot program. Journal of Opioid Management 2005; 1: 147–151
   PubMedGoogle Scholar
• McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the addiction severity index. Journal of Substance Abuse Treatment 1992; 9: 199–213
   PubMed Web of Science ®Google Scholar
• McMillan GP, Lapham SC. Staff perspectives on methadone maintenance therapy (MMT) in a large southwestern jail. Addiction Research & Theory 2005; 13: 53–63
   Web of Science ®Google Scholar
• Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence Cochrane Database of Systematic Reviews. 2006, Issue 1. DOI 10.1002/14651858
   Google Scholar
• Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisoners 2004 (Rep. No. Special Report). U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. 2006
   Google Scholar
• Murphy SA, Lynch KG, Oslin D, McKay JR, TenHave T. Developing adaptive treatment strategies in substance abuse research. Drug and Alcohol Dependence 2007; 88: S24–S30
   PubMed Web of Science ®Google Scholar
• Needels K, James-Burdumy S, Burghardt J. Community case management for former jail inmates: Its impacts on rearrest, drug use, and HIV risk. Journal of Urban Health: Bulletin of the New York Academy of Medicine 2005; 82: 420–433
   PubMed Web of Science ®Google Scholar
• Ngo HT, rnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008; 32: 23–28
   PubMed Web of Science ®Google Scholar
• O’Brien C, Cornish JW. Naltrexone for probationers and parolees. Journal of Substance Abuse Treatment 2006; 31: 107–111
   PubMed Web of Science ®Google Scholar
• Office for Human Research Protections (OHRP). Guidance on the involvement of prisoners in research. Department of Health and Human Services. 2003, Available from: http://www.hhs.gov/ohrp/humansubjects/guidance/prisoner.htm
   Google Scholar
• Patapis NS, Nordstrom BR. Research on naltrexone in the criminal justice system. Journal of Substance Abuse Treatment 2006; 31: 113–115
   PubMedGoogle Scholar
• Pearson FS, Lipton DS. A meta-analytic review of the effectiveness of corrections-based treatments for drug abuse. The Prison Journal 1999; 79: 384–410
   Google Scholar
• Perry A, Coulton S, Glanville J, Godfrey C, Lunn J, McDougall C, Neale Z. Interventions for drug-using offenders in the courts, secure establishments and the community. Cochrane Database of Systematic Reviews 2006, 3, Art. No.: CD005193. DOI: 10.1002/14651858. CD005193.pub 2
   PubMedGoogle Scholar
• Rothman KJ, Greenland S, Lash TL. Modern epidemiology3rd. Lippincott Williams and Wilkins, Philadelphia 2008
   Google Scholar
• Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: Database linkage study. British Medical Journal 1998; 316: 426–428
   PubMed Web of Science ®Google Scholar
• Shearer J, Wodak AD, Dolan KA. Evaluation of a prison-based naltrexone program. International Journal of Prisoner Health 2007; 3: 214–224
   Google Scholar
• Shewan D, Gemmell M, Davies JB. Prison as a modifier of drug using behaviour. Addiction Research and Theory 1994; 2: 203–215
   Google Scholar
• Stallwitz A, Stover H. The impact of substitution treatment in prisons–A literature review. International Journal of Drug Policy 2007; 18: 464–474
   PubMed Web of Science ®Google Scholar
• Stewart LM, Henderson CJ, Hobbs MS, Ridout SC, Knuiman MW. Risk of death in prisoners after release from jail. Australian and New Zealand Journal of Public Health 2004; 28: 32–36
   PubMed Web of Science ®Google Scholar
• Stover H, Hennebel LC, Casselman J. Substitution treatment in European prisons–A study of policies and practices of substitution treatment in prisons in 18 European countries. The European Network of Drug Services in Prison, Cranstoun Drug Services, London 2004
   Google Scholar
• Sullivan CJ, McKendrick K, Sacks S, Banks S. Modified therapeutic community treatment for offenders with MICA disorders: Substance use outcomes. American Journal of Drug and Alcohol Abuse 2007; 33: 823–832
   PubMed Web of Science ®Google Scholar
• Tait RJ, Ngo HT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. Journal of Substance Abuse Treatment 2007, In press
   PubMedGoogle Scholar
• Taxman FS, Perdoni ML, Harrison LD. Drug treatment services for adult offenders: The state of the state. Journal of Substance Abuse Treatment 2007; 32: 239–254
   PubMed Web of Science ®Google Scholar
• TenHave TR, Coyne J, Salzer M, Katz I. Research to improve the quality of care for depression: Alternatives to the simple randomized clinical trial. General Hospital Psychiatry 2003; 25: 115–123
   PubMed Web of Science ®Google Scholar
• Tucker JA, Roth DL. Extending the evidence hierarchy to enhance evidence-based practice for substance use disorders. Addiction 2006; 101: 918–932
   PubMed Web of Science ®Google Scholar
• Vandevelde S, Broekaert E, Schuyten G, Van Hove G. Intellectual abilities and motivation toward substance abuse treatment in drug-involved offenders: A pilot study in the Belgian criminal justice system. International Journal of Offender Therapy and Comparative Criminology 2005; 49: 277–297
   PubMed Web of Science ®Google Scholar
• van Olphen J, Freudenberg N, Fortin P, Galea S. Community reentry: Perceptions of people with substance use problems returning home from New York City jails. Journal of Urban Health 2006; 83: 372–381
   PubMed Web of Science ®Google Scholar
• Waal H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998–2004. European Addiction Research 2007; 13: 66–73
   PubMedGoogle Scholar
• Waal H, Frogopsahl G, Olsen L, Christophersen AS, Morland J. Naltrexone implants–Duration, tolerability and clinical usefulness. A pilot study. European Addiction Research 2006; 12: 138–144
   PubMed Web of Science ®Google Scholar
• Wexler HK, Fletcher BW. National criminal justice drug abuse treatment studies (CJ-DATS) overview. The Prison Journal 2007; 87: 9–24
   Web of Science ®Google Scholar
• Willette RE. The development of sustained action preparations of narcotic antagonists. NIDA Research Monograph 1978; 19: 333–339
   Google Scholar